Related Experiment Video
Updated: Oct 16, 2025
06:54
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
2.9K
Moyamoya disease in Mexico: our experience
E Nathal1, A Serrano-Rubio1, E Maciel2
1Departamento de Neurocirugía, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, Mexico.
Neurologia
|October 16, 2021
Summary
Surgical revascularisation significantly lowers disability scores and prevents recurrent vascular events in moyamoya disease (MD) patients. This study highlights revascularisation as a key treatment to improve neurological outcomes for MD.
Area of Science:
- Neurology
- Neurosurgery
- Vascular Medicine
Background:
- Moyamoya disease (MD) is a progressive occlusive condition affecting anterior cerebral circulation, leading to ischemia or hemorrhage.
- Current management focuses on preventing cerebrovascular events via surgical revascularization or pharmacologic therapy.
Purpose of the Study:
- To evaluate the efficacy of surgical revascularization versus pharmacologic treatment in managing moyamoya disease (MD) and moyamoya syndrome (MS).
- To assess the impact of treatment on neurological status and recurrence of vascular events in a Hispanic patient cohort.
Main Methods:
- Retrospective study of 17 patients (14 MD, 3 MS) diagnosed between 1989 and 2016.
- Patients were treated with either surgical revascularization (10 patients) or pharmacologic therapy (7 patients).
- Outcomes were assessed using the modified Rankin Scale (mRs) and monitoring for recurrent vascular events.
Main Results:
- Surgical revascularization resulted in significantly lower mRs scores compared to pharmacologic treatment (P < .04).
- No recurrences were observed in patients who underwent revascularization, while 2 patients on pharmacologic treatment experienced new vascular events (P < .05).
- No significant differences in outcomes were noted among various revascularization techniques.
Conclusions:
- Surgical revascularization is effective in improving neurological status and preventing recurrent cerebrovascular events in patients with moyamoya disease.
- This study represents the largest published series of Hispanic individuals with MD, supporting revascularization as a primary treatment strategy.
- The findings underscore the importance of surgical intervention for better patient outcomes in moyamoya disease.
Keywords:
Adult moyamoya diseaseCerebral haemorrhageCerebral ischaemiaCirugía de revascularizaciónEnfermedad moyamoyaEnfermedad moyamoya en adultos.Hemorragia cerebralIsquemia cerebralMoyamoya diseasePharmacological treatmentRevascularisation surgeryTratamiento médicoMore Related Videos
Related Concept Videos
01:22Mitral Stenosis I: Introduction
82
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
82
01:26Mitral Stenosis III: Medical Management
44
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
44
01:30Coronary Artery Disease III: Clinical Manifestations
73
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
73
01:30Cardiomyopathy II: Dilated Cardiomyopathy
74
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
74
01:30Coronary Artery Disease I: Introduction
485
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
485
01:14Myocarditis III: Medical Management
31
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
31